LLS TAP Announces Five New Investments Supporting Next Generation Immunotherapies

news
Written By Mollie Rotmensch

The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) made a strategic investment in Immune-Onc.

Mollie Rotmensch
Previous

FDA clears Immune-Onc to start trial of Keytruda combo in solid-tumor patients
Next

Immune-Onc ratchets up a series B1 and B2 for $73M